3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors

Onion, David; Argent, Richard H.; Reece-Smith, Alex M.; Craze, Madeleine L.; Pineda, Robert G.; Clarke, Philip A.; Ratan, Hari L.; Parsons, Simon L.; Lobo, Dileep N.; Duffy, John P.; Atherton, John C.; McKenzie, Andrew J.; Kumari, Rajendra; King, Peter; Hall, Brett M.; Grabowska, Anna M.

doi:10.1158/1535-7163.MCT-15-0598

All Outputs (2)

Penetration and uptake of Nanoparticles in 3D tumour spheroids (2019)
Journal Article
Tchoryk, A., Taresco, V., Argent, R., Ashford, M. B., Gellert, P., Stolnik, S., …Garnett, M. C. (2019). Penetration and uptake of Nanoparticles in 3D tumour spheroids. Bioconjugate Chemistry, 30(5), 1371-1384. https://doi.org/10.1021/acs.bioconjchem.9b00136

Animal models are effective for assessing tumour localisation of nanosystems, but difficult to use for studying penetration beyond the vasculature. Here, we have used well-characterised HCT116 colorectal cancer spheroids to study the effect of nanopa... Read More about Penetration and uptake of Nanoparticles in 3D tumour spheroids.

3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors (2016)
Journal Article
Onion, D., Argent, R. H., Reece-Smith, A. M., Craze, M. L., Pineda, R. G., Clarke, P. A., …Grabowska, A. M. (2016). 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Molecular Cancer Therapeutics, 15(4), https://doi.org/10.1158/1535-7163.MCT-15-0598

There is a growing recognition that current preclinical models do not reflect the tumor microenvironment in cellular, biological, and biophysical content and this may have a profound effect on drug efficacy testing, especially in the era of molecular... Read More about 3-dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors.